870997-87-8

Usage

Uses

Used in Pharmaceutical Industry:
N-Methyl-2-aminopyridine-3-carboxamide is used as a chemical intermediate for the preparation of triazolopyrazine derivatives and analogs. These compounds are of significant interest due to their potential as c-MET kinase activity inhibitors.
As c-MET Kinase Inhibitors:
N-Methyl-2-aminopyridine-3-carboxamide is utilized in the development of c-MET kinase inhibitors, which are important for the treatment of various diseases, including cancer. The c-MET kinase is a receptor tyrosine kinase involved in cell proliferation, survival, and migration. Inhibition of this kinase can lead to the suppression of tumor growth and metastasis, making it a promising target for therapeutic intervention.
In the synthesis of triazolopyrazine derivatives and analogs, N-Methyl-2-aminopyridine-3-carboxamide serves as a building block, providing the necessary structural features for the formation of biologically active compounds. These derivatives have the potential to modulate c-MET kinase activity, thereby offering new treatment options for patients with cancer and other diseases where c-MET kinase plays a critical role.

InChI:InChI=1/C7H9N3O/c1-9-7(11)5-3-2-4-10-6(5)8/h2-4H,1H3,(H2,8,10)(H,9,11)

Upstream product

• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 74-89-5 methylamine 
• 593-51-1 methylamine hydrochloride 
• 13362-26-0 2-aminopyridine-3-carboxylic acid ethyl ester 

Downstream Products

• 41803-82-1 3-Methyl-2-phenylpyrido<2,3-d>pyrimidin-4(3H)-on 

Relevant academic research and scientific papers

BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS

The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

INHIBITORS OF FOCAL ADHESION KINASE

The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents are as defined herein. The invention also provides a method of using the inhibitors in treatment of cancer, and methods of preparation of the inhibitors by use of coupling reactions.

QUINAZOLINE DERIVATIVE

This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R 1 represents a lower alkyl group et al; R 2 and R 3 are same and different and represents hydrogen atm et al; R 4 represents the substituent of the formula (II) et al; X 1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

Synthesis and pharmacological activity of triazole derivatives inhibiting eosinophilia

In order to develop novel antiasthmatic agents based on a new mechanism of action, a series of 3-substituted 5-amino-1- [(methylamino)(thiocarbonyl)]-1H-1,2,4-triazole derivatives were synthesized and evaluated in a model in which eosinophilia was induced in the airway through intravenous (iv) injection of Sephadex particles on days 0, 2, and 5. After screening of several hundred derivatives, we finally identified the highly potent eosinophilia inhibitor 5-amino-3-(4-chlorophenyl)-1- [(methylamino)(thiocarbonyl)]-1H-triazole (23c, GCC-AP0341), which had ID50 values of 0.3 and 0.07 mg/kg when administered orally (os) and intraperitoneally (ip), respectively. This compound showed complete inhibition of the hypersensitivity induced by ascaris inhalation at an ip dose of 1 mg/kg as well as low toxicity, with an LD50 value of >2.0 g/kg in mice. Extensive study of its mechanism of action revealed that 23c inhibited eosinophil survival induced by interleukin-5 (IL-5), but had little or no effect on leukotriene D4 (LTD4) or platelet-activating factor (PAF)- induced responses. Taken together, these results suggest 23c as a novel candidate for the treatment of chronic asthma. Further studies are now underway.